Compositions And Methods For Treating Mucopolysaccharidosis IIIA
Provided herein are compositions and methods for treating Mucopolysaccharidosis IIIA (MPS IIIA) comprising enzyme replacement therapy and gene therapy constructs described herein.
1 . A variant human N-sulfoglucosamine sulfohydrolase (SGSH) protein, wherein the variant human SGSH protein comprises at least one mutation selected from A482Y and E488V compared to SEQ ID NO:1, and wherein the native signal peptide corresponding to amino acid residues 1-20 of SEQ ID NO:1 is replaced with a signal peptide comprising a sequence selected from the group consisting of SEQ ID NOs: 22-27.
2 . The variant human SGSH protein of claim 1 , wherein the variant SGSH protein comprises the A482Y mutation.
3 . The variant human SGSH protein of claim 1 , wherein the variant SGSH protein comprises the E488V mutation.
4 . The variant human SGSH protein of claim 1 , wherein the variant SGSH protein comprises the A482Y mutation and the E488V mutation.
5 . The variant human SGSH protein of claim 2 , wherein the variant SGSH protein comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 2.
6 . The variant human SGSH protein of claim 5 , wherein the variant SGSH protein comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 2.
7 . The variant human SGSH protein of claim 6 , wherein the variant SGSH protein comprises the amino acid sequence of SEQ ID NO: 2.
8 . The variant human SGSH protein of claim 3 , wherein the variant SGSH protein comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 3.
9 . The variant human SGSH protein of claim 8 , wherein the variant SGSH protein comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 3.
10 . The variant human SGSH protein of claim 9 , wherein the variant SGSH protein comprises the amino acid sequence of SEQ ID NO: 3.
11 . The variant human SGSH protein of claim 4 , wherein the variant SGSH protein comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 4.
12 . The variant human SGSH protein of claim 11 , wherein the variant SGSH protein comprises an amino acid sequence that is at least 98% identical to SEQ ID NO: 4.
13 . The variant human SGSH protein of claim 12 , wherein the variant SGSH protein comprises the amino acid sequence of SEQ ID NO: 4.
14 . The variant human SGSH protein of any one of claims 1 to 13 , wherein the signal peptide is a non-native signal peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-27.
15 . The variant human SGSH protein of any one of claims 1 to 14 , wherein the variant human SGSH protein further comprises a lysosomal cleavage peptide.
16 . The variant human SGSH protein of any one of claims 1 to 15 , further comprising a variant insulin-like growth factor 2 (vIGF2) peptide.
17 . The variant human SGSH protein of claim 16 , wherein the vIGF2 peptide is N terminal to the variant human SGSH protein.
18 . The variant human SGSH protein of claim 16 , wherein the vIGF2 peptide is C terminal to the variant human SGSH protein.
19 . The variant human SGSH protein of any one of claims 16 to 18 , wherein the vIGF2 peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 29-91.
20 . The variant human SGSH protein of any one of claims 16 to 18 , wherein the vIGF2 peptide comprises an amino acid sequence that is at least 98% identical to a SEQ ID NO:40 or SEQ ID NO:41.
21 . A nucleic acid construct encoding the variant human SGSH protein of any one of claims 1 to 20 .
22 . A gene therapy vector comprising the nucleic acid construct of claim 21 .
23 . The gene therapy vector of claim 22 , wherein the gene therapy vector is a virus vector.
24 . The gene therapy vector of claim 23 , wherein the virus vector is an adenovirus vector, an adeno-associated virus (AAV) vector, a retrovirus vector, a lentivirus vector, a pox virus vector, a vaccinia virus vector, an adenovirus vector, or a herpes virus vector.
25 . The gene therapy vector of claim 24 , wherein the AAV vector is an AAV1 vector, an AAV2 vector, an AAV3 vector, an AAV4 vector, an AAV5 vector, an AAV6 vector, an AAV7 vector, an AAV8 vector, an AAV9 vector, an AAVrhS vector, an AAVrh10 vector, an AAVrh33 vector, an AAVrh34 vector, an AAVrh74 vector, an AAV Anc80 vector, an AAV-PHP.B vector, an AAVhu68 vector, an AAV-DJ vector, an AAV2/9 vector, a TM-AAV6 vector, an AAV-PHP.A vector, an AAV-PHP.S vector or an AAV-PHPeB vector.
26 . The nucleic acid construct of claim 21 , wherein the nucleic acid construct is a plasmid.
27 . A pharmaceutical composition comprising a therapeutically effective amount of the nucleic acid construct of any one of claims 21 to 26 , or the gene therapy vector of any one of claims 22 to 25 , and a pharmaceutically acceptable carrier or excipient.
28 . The pharmaceutical composition of claim 27 , wherein the excipient comprises a non-ionic, low-osmolar compound, a buffer, a polymer, a salt, or a combination thereof.
29 . A method for treating Mucopolysaccharidosis IIIA (MPS IIIA) comprising administering to a subject in need thereof the pharmaceutical composition of claim 27 or claim 28 .
30 . The method of claim 29 , wherein the administering is performed intrathecally, intraocularly, intravitreally, retinally, intravenously, intramuscularly, intraventricularly, intracerebrally, intracerebellarly, intracerebroventricularly, intraperenchymally, subcutaneously, intradermally or topically, or via a combination thereof.
31 . The nucleic acid construct of any one of claims 21 to 26 , or the gene therapy vector of any one of claims 22 to 25 for use in preparation of a medicament for treating MPS IIIA.
32 . A pharmaceutical composition comprising the variant human SGSH protein of any one of claims 1 to 20 and a pharmaceutically acceptable carrier or excipient.
33 . A method of treating MPS IIIA, comprising administering the pharmaceutical composition of claim 33 to a subject in need thereof.
34 . The method of claim 33 , wherein the administering is performed intrathecally, intraocularly, intravitreally, retinally, intravenously, intramuscularly, intraventricularly, intracerebrally, intracerebellarly, intracerebroventricularly, intraperenchymally, subcutaneously, or a combination thereof.
35 . The method of any one of claims 29-30, 33 and 34 , wherein administering the pharmaceutical composition prevents, reduces or reverses accumulation of heparan sulfate in the subject.